U.S. pharma large copyright scrapped two experimental weight loss drugs very last year—a after-daily pill, lotiglipron, because of elevated liver enzymes and a twice-everyday pill, danuglipron, because of robust Uncomfortable side effects—but CEO Albert Bourla has mentioned the company is decided to “Enjoy and get” within the weight problem